Device Trial Radar · NCT06751576
Retrospective Clinical Trial Comparing Radiologists' Diagnosis Accuracy in Lung Cancer Screening Population With and Without the Help of an AI/ML Tech-based SaMD
Last checked: Nov 19, 2026Latest source record: May 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
480
Actual
Start
Sep 21, 2022
Primary completion
Jan 31, 2025
Study completion Mar 12, 2025
Sponsor
- Lead sponsor
- Median TechnologiesNot on our public-company list
- Sponsor type
- Industry
- First posted
- Dec 30, 2024
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 50 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a two arm, randomized, controlled, blinded, multi-case multi reader (MRMC), retrospective study for the evaluation of the efficacy and safety of an AI/ML technology-based CADe/x developed to detect, localize and characterize malignancy score of pulmonary nodules on LDCT chest scans taken as part of a lung cancer screening program. LDCT DICOM images of patients who underwent routine lung cancer screening will be selected and enrolled into the study. Enrolled scans analyzed by radiologists with the assistance of the Median LCS (formerly iBiopsy) device are compared to the analysis by radiologists without the assistance of the Median LCS device. Figures of merit for patient level and lesion level detection and diagnostic efficacy will be calculated and compared, sub-class analysis will be performed to ensure device generalizability.
Conditions
- High Risk Cancer
- Lung Cancer
Interventions
Median LCSDevice
End-to-end processing of chest LDCT DICOM images by an AI/ML tech-based SaMD to detect, localize, and characterize (assign a malignancy score) each detected pulmonary nodule. The output of the device is a DICOM File (Median LCS result report) summarizing results per patient.
Primary outcomes
What the sponsor says the trial is designed to measure.
- ∆ AUC of ROCs > 0. Delta Area between the Response operating curve (AUROC) value with Median LCS and AUROC without Median LCS at patient level data is superior to 0.Time frame: 12 months
Locations
5 sites in 2 countries. Site status is shown where the registry gives one.
University of Pennsylvania - Penn Center for Innovation
Philadelphia, Pennsylvania
Baptist Clinical Research Institute
Memphis, Tennessee
The University of Texas M.D. Anderson Cancer Center
Houston, Texas
2 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.